The current worldwide value of drugs and devices for the treatment of obesity stands at $750 million, representing a minor share of the combined potential market expected for these products over the next decade as rates of obesity incidence and prevalence surge and as recognition of its healthcare cost drives development of effective [...]
bookmark to
